Alnylam Pharmaceuticals financials
$254.07−0.51%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.29B | $1.17B | $1.10B | $1.25B | $773.7M | $594.2M | $593.2M | $500.9M | $659.8M | $494.3M | $439.7M | $750.5M |
| Gross profit | $992.7M | $959.7M | $829.3M | $1.05B | $631.7M | $524.0M | $490.5M | $418.9M | $592.6M | $439.7M | $396.1M | $666.2M |
| Gross margin | 76.9% | 82.2% | 75.6% | 84.2% | 81.6% | 88.2% | 82.7% | 83.6% | 89.8% | 89.0% | 90.1% | 88.8% |
| Operating income | $231.4M | $268.6M | $131.7M | $368.0M | -$16.2M | $18.1M | -$105.2M | -$76.9M | $48.6M | -$43.4M | -$116.4M | $213.9M |
| Net income | $164.5M | $206.0M | $186.4M | $251.1M | -$72.2M | -$18.3M | -$83.8M | -$111.6M | -$16.9M | -$65.9M | -$137.9M | $147.8M |
| Net margin | 12.7% | 17.6% | 17.0% | 20.1% | −9.3% | −3.1% | −14.1% | −22.3% | −2.6% | −13.3% | −31.4% | 19.7% |
| Diluted EPS | $1.21 | $1.51 | $1.32 | $1.84 | $-0.55 | $-0.14 | $-0.65 | $-0.87 | $-0.13 | $-0.52 | $-1.15 | $1.15 |
| EBITDA | $245.3M | $282.2M | $145.2M | $381.8M | -$2.3M | $32.5M | -$91.0M | -$62.9M | $63.6M | -$29.9M | -$116.4M | $227.2M |
| Operating cash flow | $326.7M | $70.5M | $163.6M | $325.1M | $129.8M | -$120.3M | -$94.7M | $43.7M | $124.2M | -$81.5M | -$29.8M | $359.4M |
| Free cash flow | $292.0M | $48.7M | $140.3M | $313.0M | $115.5M | -$129.3M | -$103.8M | $39.5M | $116.1M | -$94.5M | -$45.1M | $342.3M |
| Diluted shares | 138.3M | 138.2M | 141.1M | 137.3M | 130.6M | 129.7M | 129.1M | 128.6M | 126.7M | 126.1M | 119.5M | 131.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.71B | $1.71B | $1.66B | $1.49B | $1.11B | $1.02B |
| Short-term investments | $1.60B | $1.30B | $1.25B | $1.23B | $1.74B | $1.61B |
| Total debt | $1.01B | $1.01B | $1.01B | $1.04B | $1.03B | $1.03B |
| Total assets | $5.56B | $5.13B | $4.97B | $4.85B | $4.57B | $4.21B |
| Total liabilities | $4.20B | $4.05B | $4.18B | $4.62B | $4.32B | $4.10B |
| Shareholders' equity | $1.35B | $1.08B | $789.2M | $233.9M | $250.6M | $115.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology